DNTH (Dianthus Therapeutics) Institutional Ownership: 92.76% (As of Jul. 05, 2026)


DNTH Dianthus Therapeutics Inc DNTH
22 GF Score
Price $94.34
GF Value $2.91
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Dianthus Therapeutics Institutional Ownership?

Dianthus Therapeutics DNTH +4.58% 22 Institutional Ownership is 92.76% as of Jul. 05, 2026. GuruFocus rates DNTH with a GF Score™ of 22/100 and a GF Value™ of $2.91 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Dianthus Therapeutics's institutional ownership is 92.76%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Dianthus Therapeutics's Insider Ownership is 0.13%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Dianthus Therapeutics's Float Percentage Of Total Shares Outstanding is 86.86%.

Dianthus Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Dianthus Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dianthus Therapeutics Institutional Ownership Chart

Dianthus Therapeutics Historical Data

The historical data trend for Dianthus Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 36.87 37.37 39.74 45.79 46.92 47.40 68.29 68.37 54.99 57.40
DNTH
22GF Score
Dianthus Therapeutics Inc DNTH
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dianthus Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 92.76% mean?
Dianthus Therapeutics (DNTH) has a Institutional Ownership of 92.76% as of Jul. 05, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Dianthus Therapeutics and its competitors.
Is Dianthus Therapeutics' Institutional Ownership too high?
Dianthus Therapeutics' current Institutional Ownership is 92.76%. Overall, Dianthus Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dianthus Therapeutics' Institutional Ownership compare to CAI and TNGX?
Dianthus Therapeutics' Institutional Ownership of 92.76% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Dianthus Therapeutics and its competitors. Dianthus Therapeutics's current Institutional Ownership is 92.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dianthus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Dianthus Therapeutics (DNTH) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.91, compared to a current price of $94.34 — trading 3141.9% above its estimated fair value. The current Institutional Ownership is 92.76%. Dianthus Therapeutics' overall GF Score™ is 22/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Dianthus Therapeutics (DNTH), the current Institutional Ownership is 92.76% as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dianthus Therapeutics (DNTH) Overvalued in 2026?

Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued. The current stock price of $94.34 is trading 3141.9% above its estimated GF Value™ of $2.91. GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.

Key valuation signals for DNTH:

  • Institutional Ownership: 92.76%
  • GF Value™: $2.91 vs. price of $94.34 (3141.9% above fair value)
  • GF Score™: 22/100 with 7 warning signs

No single metric tells the full story. See the DNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dianthus Therapeutics Business Description

Other Exchanges 87E:Germany
Address 7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
22GF Score

Get the complete analysis for DNTH

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$94.34
Price
$2.91
GF Value